Filing an orphan drug designation application with the FDA for MANF in Retinitis Pigmentosa and immediately thereafter will be submitting a second ocular orphan drug application for MANF with the FDA - See more at:

http://www.thechairmansblog.com/amarantus-bio...Lafz3.dpuf